Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Collaborate with Regeneron to Research, Develop & Commercialise","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"EUROPE","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Orbit Discovery"},{"orgOrder":0,"company":"Embark Biotech","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$511.1 million","upfrontCash":"$16.2 million","newsHeadline":"Novo Nordisk Acquires Embark Biotech, Including its Lead Asset Targeting Obesity and Other Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Embark Biotech"},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Deep Apple Therapeutics"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Lexaria Bioscience"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Lexaria Bioscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

              Details:

              DehydraTECH-CBD (cannabidiol) is a DehydraTECH-processed CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of diabetes and weight loss.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Nutrition and Weight Loss Product Name: DehydraTECH-CBD

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Deep Apple Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning ...

              Details:

              The net proceeds will be used for advancing multiple novel small molecule therapeutics focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Apple Tree Partners

              Deal Size: $52.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Embark Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novo Nordisk Acquires Embark Biotech, Including its Lead Asset Targeting Obesity and Other Cardiometabolic Diseases

              Details:

              Under the acquisition, Novo Nordisk receives the full rights to develop and commercialize the lead program to treat obesity and related co-morbidities.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Novo Nordisk

              Deal Size: $511.1 million Upfront Cash: $16.2 million

              Deal Type: Acquisition August 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orbit Discovery

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Europe
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics

              Details:

              The collaboration aims to accelerate Endevica’s development of advanced GPCR-targeting therapeutics on receptor sets both novel and complimentary to its lead compound to creat first-in-class therapeutics for cachexia caused by cancer and other chronic conditions.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Peptide

              Partner/Sponsor/Collaborator: Endevica Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Regeneron Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca Collaborate with Regeneron to Research, Develop & Commercialise

              Details:

              AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY